SynthesisScientific reports2025
Association of IL-37 levels and genetic variants with systemic lupus erythematosus: a meta-analysis.
Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- IL-37 and Neuroimmune Mechanisms Relevant to Depressive and Anxiety Disorders: A Scoping Review.International journal of molecular sciences · 2026Article
- From pathogenesis to precision medicine in systemic lupus erythematosus: Emerging biomarkers and targeted interventions.iScience · 2026Review
- Anti-Inflammatory Cytokine Signatures in Primary Glaucoma Subtypes: Diagnostic and Pathophysiological Insights From IL-36Ra, IL-37, and IL-38.Journal of ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study examined the association between circulating interleukin-37 (IL-37) levels and systemic lupus erythematosus (SLE), as well as the relationship between IL-37 gene polymorphisms and susceptibility to SLE. Relevant studies were identified through extensive searches of the Medline, Embase, and Web of Science databases up to December 2024. A meta-analysis was conducted to compare serum/plasma IL-37 levels in SLE patients with those in controls and to evaluate the association between IL-37 gene polymorphisms and SLE risk. Twelve studies comprising 1,229 SLE patients and 745 controls were analyzed. The meta-analysis revealed higher IL-37 levels in SLE patients compared to controls (SMD: 0.570, 95% CI-0.070-1.210, p = 0.0803), though the difference was not statistically significant. Subgroup analysis showed a significant association in Asians (SMD: 0.730, 95% CI: 0.151-1.310, p = 0.010), but not in Arabs (SMD: 0.410, 95% CI: -0.780-1.600, p = 0.500). Analysis of the original data indicated significant results (SMD: 1.026, 95% CI: 0.505-1.547, p < 0.001), while the re-calculated data did not. Studies conducted before 2019 revealed a significant association (SMD: 0.906, 95% CI: 0.438-1.374, p < 0.001), unlike more recent studies. Higher IL-37 levels were observed in patients with lupus nephritis, although these findings were not statistically significant. Genetic analysis of IL-37 rs3811047 polymorphism revealed no significant association in Arabs (OR: 1.432, 95% CI: 0.607-3.373, p = 0.413), whereas a significant association was noted in Asians (OR: 0.649, 95% CI: 0.448-0.941, p = 0.023). The meta-analysis demonstrated significantly elevated IL-37 levels in SLE patients among Asians, along with a significant association between IL-37 polymorphisms and SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.